Aurélie Thedrez1, Dirk J Blom1, Stéphane Ramin-Mangata1, Valentin Blanchard1, Mikaël Croyal1, Kévin Chemello1, Brice Nativel1, Matthieu Pichelin1, Bertrand Cariou1, Steeve Bourane1, Lihua Tang1, Michel Farnier1, Frederick J Raal1, Gilles Lambert2. 1. From the CRNH Ouest, INRA UMR 1280 PhAN (A.T., V.B., M.C., G.L.) and L'institut du thorax, INSERM UMR 1087, CNRS UMR 6291 (A.T., M.P., B.C.), Université de Nantes, France; L'institut du thorax, CHU de Nantes, CIC Endocrino-Nutrition, France (A.T., M.P., B.C.); Lipidology Division of Internal Medicine, University of Cape Town, South Africa (D.J.B.); INSERM UMR 1188 DéTROI, Université de La Réunion, Sainte Clotilde, France (S.R.-M., V.B., K.C., B.N., S.B., G.L.); Amgen, Thousand Oaks, CA (L.T.); CHU Dijon Bourgogne, Point Médical, France (M.F.); and Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa (F.J.R.). 2. From the CRNH Ouest, INRA UMR 1280 PhAN (A.T., V.B., M.C., G.L.) and L'institut du thorax, INSERM UMR 1087, CNRS UMR 6291 (A.T., M.P., B.C.), Université de Nantes, France; L'institut du thorax, CHU de Nantes, CIC Endocrino-Nutrition, France (A.T., M.P., B.C.); Lipidology Division of Internal Medicine, University of Cape Town, South Africa (D.J.B.); INSERM UMR 1188 DéTROI, Université de La Réunion, Sainte Clotilde, France (S.R.-M., V.B., K.C., B.N., S.B., G.L.); Amgen, Thousand Oaks, CA (L.T.); CHU Dijon Bourgogne, Point Médical, France (M.F.); and Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa (F.J.R.). gilles.lambert@univ-reunion.fr.
Abstract
OBJECTIVE: Evolocumab, a PCSK9 (proprotein convertase subtilisin kexin type 9)-neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemic (HoFH) patients with reduced LDLR (low-density lipoprotein receptor) function. However, their individual responses are highly variable, even among carriers of identical LDLR genetic defects. We aimed to elucidate why HoFH patients variably respond to PCSK9 inhibition. APPROACH AND RESULTS: Lymphocytes were isolated from 22 HoFH patients enrolled in the TAUSSIG trial (Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders). Ten patients were true homozygotes (FH1/FH1) and 5 identical compound heterozygotes (FH1/FH2). Lymphocytes were plated with or without mevastatin, recombinant PCSK9 (rPCSK9), or a PCSK9-neutralizing antibody. Cell surface LDLR expression was analyzed by flow cytometry. All HoFH lymphocytes had reduced cell surface LDLR expression compared with non-FH lymphocytes, for each treatment modality. Lymphocytes from FH1/FH2 patients (LDLR defective/negative) displayed the lowest LDLR expression levels followed by lymphocytes from FH1/FH1 patients (defective/defective). Mevastatin increased, whereas rPCSK9 reduced LDLR expression. The PCSK9-neutralizing antibody restored LDLR expression. Lymphocytes displaying higher LDLR expression levels were those isolated from patients presenting with lowest levels of LDL-C and apolipoprotein B, before and after 24 weeks of evolocumab treatment. These negative correlations remained significant in FH1/FH1 patients and appeared more pronounced when patients with apolipoprotein E3/E3 genotypes were analyzed separately. Significant positive correlations were found between the levels of LDLR expression and the percentage reduction in LDL-C on evolocumab treatment. CONCLUSIONS: Residual LDLR expression in HoFH is a major determinant of LDL-C levels and seems to drive their individual response to evolocumab.
OBJECTIVE:Evolocumab, a PCSK9 (proprotein convertase subtilisin kexin type 9)-neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemic (HoFH) patients with reduced LDLR (low-density lipoprotein receptor) function. However, their individual responses are highly variable, even among carriers of identical LDLRgenetic defects. We aimed to elucidate why HoFH patients variably respond to PCSK9 inhibition. APPROACH AND RESULTS: Lymphocytes were isolated from 22 HoFH patients enrolled in the TAUSSIG trial (Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders). Ten patients were true homozygotes (FH1/FH1) and 5 identical compound heterozygotes (FH1/FH2). Lymphocytes were plated with or without mevastatin, recombinant PCSK9 (rPCSK9), or a PCSK9-neutralizing antibody. Cell surface LDLR expression was analyzed by flow cytometry. All HoFH lymphocytes had reduced cell surface LDLR expression compared with non-FH lymphocytes, for each treatment modality. Lymphocytes from FH1/FH2 patients (LDLR defective/negative) displayed the lowest LDLR expression levels followed by lymphocytes from FH1/FH1patients (defective/defective). Mevastatin increased, whereas rPCSK9 reduced LDLR expression. The PCSK9-neutralizing antibody restored LDLR expression. Lymphocytes displaying higher LDLR expression levels were those isolated from patients presenting with lowest levels of LDL-C and apolipoprotein B, before and after 24 weeks of evolocumab treatment. These negative correlations remained significant in FH1/FH1patients and appeared more pronounced when patients with apolipoprotein E3/E3 genotypes were analyzed separately. Significant positive correlations were found between the levels of LDLR expression and the percentage reduction in LDL-C on evolocumab treatment. CONCLUSIONS: Residual LDLR expression in HoFH is a major determinant of LDL-C levels and seems to drive their individual response to evolocumab.
Authors: Evan A Stein; Narimon Honarpour; Scott M Wasserman; Feng Xu; Rob Scott; Frederick J Raal Journal: Circulation Date: 2013-09-06 Impact factor: 29.690
Authors: Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2017-01-05 Impact factor: 8.311
Authors: Rocco Romagnuolo; Corey A Scipione; Michael B Boffa; Santica M Marcovina; Nabil G Seidah; Marlys L Koschinsky Journal: J Biol Chem Date: 2015-03-16 Impact factor: 5.157
Authors: Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein Journal: Lancet Date: 2014-10-01 Impact factor: 79.321
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Na Wang; Lishu He; Hui Lin; Lunbo Tan; Yuan Sun; Xiaoying Zhang; A H Jan Danser; Hong S Lu; Yongcheng He; Xifeng Lu Journal: PLoS One Date: 2020-05-21 Impact factor: 3.240
Authors: Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin Journal: Arterioscler Thromb Vasc Biol Date: 2019-10-03 Impact factor: 8.311